Scientists at the University of California, San Francisco have identified a compound that shows promise in treating Alzheimer's disease. The research, published Wednesday in Science Translational Medicine, demonstrates that the molecule can reduce toxic protein accumulation in animal models.
The compound, called ALZ-101, targets amyloid-beta and tau proteins—the two main pathological features of Alzheimer's. In mouse models, treatment reduced amyloid plaques by 67% and tau tangles by 54% over six months.
"What's exciting is that we're seeing not just reduction of pathology, but actual improvement in cognitive function," said senior author Dr. Maria Chen. "Treated animals performed significantly better on memory tests than untreated controls."
Alzheimer's disease affects approximately 55 million people worldwide, with numbers projected to nearly double every 20 years. Current treatments provide only modest symptomatic relief and do not alter disease progression.
The research team plans to begin Phase I clinical trials later this year. If successful, ALZ-101 could become the first disease-modifying treatment for Alzheimer's, potentially benefiting millions of patients and their families.